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Abstract 
BACKGROUND: Penile cancer accounts for 0.4-0.6% of all malignancy in men in Europe and the United States 
of America. It also accounts for 10% of all malignancy in men in some Asian, South American, and African 
countries. P53 protein has the function to regulate apoptosis in the cell cycle. Therefore, the presence of p53 in 
cells may indicate higher proliferative activity of the cells as a feedback mechanism, indicating disease 
progression.  
AIM: This study aims to identify the association between p53 expression and survival rate in penile cancer 
patients. 
METHODS: This study was a retrospective observational analytic study. This study was conducted in Pathology 
Anatomy Laboratory Faculty of the Medicine University of Sumatera Utara/Haji Adam Malik Hospital/University of 
Sumatera Utara Hospital to assess p53 expression. This study was conducted from January 2018 to December 
2018. 
RESULTS: The total subjects in this study were 33 with the mean age of 50.79 ± 10.62. Based on clinical stage, 
patients in this study are divided into 11 patients (33.3%) in stage T II and 22 patients (66.7%) in stage T III/T IV. 
P53 expression was positive in 13 patients (35.3%). There were 19 patients (57.6) alive and 14 patients (42.4%) 
deceased. Statistical analysis using chi-square showed that there was an association between p53 expression 
and mortality (p = 0.011). In the Kaplan-Meier Curve for 3-year overall survival based on p53 expression, the 
survival rate in 36 months in the p53 positive group is 18%, while in p53 negative group, the survival rate was 
60%. The survival rate based on p53 status was significantly different (p = 0.025). 
CONCLUSION: There is a significant association between p53 expression and mortality in penile cancer patients. 
In conclusion, p53 expression in penile cancer cells examined by immunohistochemistry may show prognostic 
values in the disease progression. 
 
 
 
Introduction 
 
Penile cancer accounts for 0.4-0.6% of all 
malignancy in men in Europe and the United States of 
America. It also accounts for 10% of all malignancy in 
men in some Asian, South American, and African 
countries [1]. In Indonesia, there were 69 men 
diagnosed with penile malignancies in Dr Cipto 
Mangunkusumo Hospital and Dharmais Hospital 
Jakarta Cancer Center for 11 years period (1994-
2005) [2]. Another study in Sanglah Hospital Bali 
showed that there were 46 penile cancer patients for 8 
years period. Meanwhile, in Haji Adam Malik Medan 
Hospital, the incidence of penile cancer for the last 4 
years (2012-2015) was 34 patients [3], [4]. 
The principal value in the management of 
penile cancer is the levitation of the tumour with good 
organ preservation along partial or total penectomy in 
regards to lowering the recurrence rate. Aside from 
the treatment of a primary tumour, the involvement of 
the lymph node remains to be an important factor in 
enhancing the patient’s prognosis. Penile cancer is an 
aggressive disease. The success rate of local lesion 
treatment is only for early stage disease. Besides, the 
more-progressive and advanced disease with the 
involvement of regional lymph node or distant 
metastasis remains a problem in the field of neuro-
oncology [4].  
The incidence of penile cancer varies within 
circumcision status, hygiene standard, phimosis, 
sexual partner, Human papilloma virus (HPV) 
infection, tobacco exposure, and other factors [1]. 
Etiologic factors known were chronic irritation from 
smegma, a product from bacterial activity in 
desquamated cells that are accumulated in the 
preputium. The most common histopathology found in 
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penile cancer is Squamous Cell Carcinoma (SCC) [5]. 
P53 protein is a product from the TP53 gene 
in the body; this protein has the function to regulate 
apoptosis in the cell cycle. The presence of p53 in 
cells may indicate higher proliferative activity of the 
cells as a feedback mechanism, indicating disease 
progression. The study showed that the excessive 
protein expression of p53 was found in penile cancer 
cells [6]. Furthermore, mutation or deletion of p53 in 
the cell may precipitate cancer to further progress [7]. 
Based on this theoretical background, p53 could be 
used to see prognosis of the disease where ass more 
expression of the protein is associated with worse 
clinical parameters [6].
 
However, the use of any 
diagnostic or prognostic tool to measure the 
expressions is not widely implemented [8].  
This rationale accelerates the urgency to do a 
study on the association between p53 expression and 
survival rate in penile cancer patients.  
 
 
Material and Methods 
 
This study was a retrospective observational 
analytic study. This study aimed to analyse the 
association between p53 expression and survival rate 
in penile cancer patients. This study was conducted in 
Pathology Anatomy Laboratory Faculty of Medicine 
University of Sumatera Utara/ Haji Adam Malik 
Hospital / University of Sumatera Utara Hospital. This 
study has the ethical approval issued by Research 
Ethics Committee Faculty of the Medicine University 
of Sumatera Utara. This study was conducted from 
January 2018 to December 2018. 
 
Immunohistochemistry of p53 
The protein expression of p53 was observed 
using Immunohistochemistry examination done on 
FFPE preparation. Specific antibodies for p53 (mouse 
monoclonal antibody) obtained from Sigma Aldrich (St 
Louis, Missouri). Preparation/micro slicing was done 
for each sample, and slides are provided for each 
sample for microscopic evaluation. 
Microscopic evaluation was performed by an 
experienced pathologist. The semiquantitative 
examination was done on random fields per specimen 
containing a minimum of 500 cells using ImageJ 
(Research Service Branch, NIH.gov) in 40 times 
magnification. The expression of the protein would be 
positive if cells were stained brownish in the 
cytoplasm or the nuclei with a granular pattern. If the 
number of positive cells exceeds 60%, the sample is 
considered positive.  
 
Results 
 
The total subjects in this study were 33 with 
the mean age of 50.79 ± 10.62. Based on clinical T 
stage, patients in this study are divided into 11 
patients (33.3%) in cT2 and 22 patients (66.7%) in 
cT3/cT4. There were 22 patients (66.7%) who had 
cancer invasion to the urethra.  
Table 1: Characteristics of the subjects 
Variable  p-Value 
Total patients 33  
Mean Age ±SD 50.79 ± 10.62 0.71** 
Clinical T stage (cT; %)  0.72* 
cT2 11 (33.3)  
cT3/cT4 22 (66.7)  
Urethral invasion (%) 22 (66.7) 0.72* 
Management (%)   
Total penectomy 18 (54.5)  
Partial penectomy 10 (30.3)  
No operation 5 (15.2)  
Chemotherapy (%) 8 (24.2) 0.416* 
p53 expression (%)   
Positive 13 (39.4)  
Negative 20 (60.6)  
Mortality status (%)   
Alive 19 (57.6)  
Deceased 14 (42.4)  
*Fisher’s Exact Test, **Mann-Whitney Test. 
 
Based on the treatment type, there were 18 
patients (54.4%) who had total penectomy, 10 
patients (30.3%) who had partial penectomy, 5 
patients (15.2%) who had no operation, and 8 patients 
(24.2%) who had completed chemotherapy cycles 
using TIP (Paclitaxel, ifosfamide, and cisplatin) 
regimen. P53 expression was positive in 13 patients 
(35.3%). There were 19 patients (57.6) alive and 14 
patients (42.4%) deceased. 
Table 2: Association between p53 expression and mortality 
p53 Expression 
Mortality 
p-Value 
Alive Deceased 
Positive 2 11 
0.011 
Negative 12 8 
 
Statistical analysis using chi-square showed 
that there was an association between p53 expression 
and mortality (p = 0.011). 
 
Figure 1: Kaplan-Meier Curve for 3-year overall survival in Penile 
Squamous Cell Carcinoma based on p53 status 
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In the Kaplan-Meier Curve for 3-year overall 
survival based on p53 expression, the survival rate in 
36 months in the p53 positive group is 18%, while in 
p53 negative group, the survival rate was 60%. The 
survival rate based on p53 status was significantly 
different (p = 0.025). 
 
 
Discussion 
 
In this study, we assessed the role of p53 
oncoprotein expression as a prognostic factor in 
penile cancer. P53 expression was analysed with the 
survival rate of penile cancer patients. In this study, 
we assessed the p53 expression as a predictor for 
mortality in penile cancer patients. Subjects were 
enrolled in one tertiary hospital which was comprised 
of the varied stage of cancer. 
In this study, p53 positive was found in 13 of 
33 patients (39.4%). By previous studies about p53 
expression, this study used 20% cut-off point for the 
nucleus staining. This positive cut-off is higher than 
the study conducted by Levi et al. (26% or 15 of 58 
cases) [9] and almost the same with the study 
conducted by Lam et al., (40% or 17 of 42 cases) [10]. 
The difference depends on the antibody reagent used.  
Compared to the previous correlation study 
with other types of cancer, this study did not find a 
correlation between p53 expression and clinical or 
histopathological variables. Cordon Carlo et al. who 
conducted a study about p53 and its correlation with 
bladder cancer found a positive correlation between 
p53 expression and vascular invasion [11]. 
Cabelguenne et al., who studied head and neck 
tumour [12], and Maeda et al., who studied carcinoma 
of the stomach, showed that p53 immunoreactivity 
was not correlated with lymph node metastasis [13]. 
On the other hand, Unal et al. noted a higher cervical 
metastasis in tongue cancer case in p53 positive [14].  
Lopes et al. showed that the immunoreactivity 
and staining stage of p53 was significantly associated 
with lymph node metastasis in N stage penile cancer 
[15]. Patient with p53 immunoreactivity had 4.8 times 
risk of having metastasis compared to a patient with 
the p53 negative. Lymphatic embolism by neoplasm 
cell and positive p53 was a single predictive factor for 
lymph node metastasis in multivariate analysis. In this 
study, metastasis was not assessed because of the 
lacking number of the patient who had metastasis, 
some of which could not be followed.  
In the study conducted by Marinescu et al., it 
is found that all (100%) of the poorly differentiated 
penile cancer had a positive expression of p53 
oncoprotein, regardless of the tumour stage. P53 was 
found in 91.2% of the moderately-differentiated 
tumour and 72.2% of the well-differentiated tumour 
[16]. Based on the tumour stage, Marinescu identified 
a positive association of p53 in all stage II and stage 
III tumour, and in 43 (84.3%) stage I tumour. In a well-
differentiated tumour, the p53 marker is in the nuclei 
of the peripheral islands of tumour cell and seldom 
isolated inside the islands, with low or moderate 
intensity. For moderately- or poorly-differentiated 
squamous penile cancer, p53 immunohistochemistry 
staining was found in the nuclei, in the peripheral 
neoplastic tumour island, with moderate or high 
intensity. The association between squamous cell 
carcinoma and carcinoma in situ was statistically 
different. In addition to that, the association between 
poorly-differentiated carcinoma and well-differentiated 
carcinoma was statistically different [16]. In this study, 
we evaluated the clinical stage of the clinical T stage 
and found no association between p53 expression 
and clinical T stage cT2 or cT3 or cT4 penile cancer. 
A prospective study conducted by Kamran-
Shostari et al. about the clinical significance of p53 
and p16 in penile cancer survival rate in North 
America revealed that p53 could be a predictor for 
penile cancer carcinoma metastasis to the lymph 
node. However, this association was only found in 
patients with the p16 negative. P16 was a predictor in 
penile carcinoma in association with HPV (Human 
Papilloma Virus) infection [17]. In another study about 
penile cancer survival, positive p53 was associated 
with bad prognosis. Ficarra et al. showed that the 
survival rate was only 34% in 47 patients with penile 
cancer. In addition to that, a patient with p53 negative 
gene expression had a 5-year- and 10-year-survival 
rate of 64.5% and 54.6%. Meanwhile, the p53 positive 
gene expression had 30.2% and 26.4%. These 
differences were significant between two groups (p = 
0.009) [18]. This study is by our study which showed 
that p53 expression is significantly different with 3-
year-survival-rate of a penile cancer patient (p = 
0.025). 
In this study, we found that p53 could be a 
predictive factor for mortality in penile cancer. 
However, this study has a limitation in the number of 
the sample and follow-up. The development of 
treatment modalities such as prophylaxis 
lymphadenectomy and chemotherapy have a role that 
should be considered for further study. Involvement of 
other than p53 gene, such as p16 should also be 
considered as a comparator. 
In conclusion, there is a significant 
association (p = 0.025) between p53 expression and 
mortality in penile cancer patients. In conclusion, p53 
expression in penile cancer cells examined by 
immunohistochemistry may show prognostic values in 
the disease progression.  
Further research is needed to assess p53 
expression and its association with treatment 
response in penile cancer patients. In addition to that, 
the involvement of other than p53 gene, such as p16 
should also be considered as a comparator. 
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